Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with acute myeloid leukemia (a type of blood cancer) who are older than 6 months of age.
- People whose leukemia cells have been confirmed to carry certain markers (called CLL-1, CD123, and/or CD33) through laboratory testing.
- People who are in reasonably good general health, as measured by a standard health scoring system, with a life expectancy of more than 3 months.
- People whose heart, liver, and kidneys are functioning well enough to meet specific laboratory test thresholds set by the trial (confirm with trial site for exact values).
- People whose hemoglobin (a measure of red blood cells) is at or above a certain minimum level.
- People who have no medical reasons preventing a cell collection procedure.
- People who are able to understand the trial and are willing to sign a written consent form.
Who may not be able to join:
- People with a serious illness or medical condition that would make it unsafe to follow the trial's treatment plan, including those with an active infection that is not under control.
- People with an active bacterial, fungal, or viral infection that has not responded to treatment.
- People with a known diagnosis of HIV, hepatitis B, or hepatitis C.
- People who are pregnant or currently breastfeeding.
- People who have taken steroid medications (glucocorticoids) as a whole-body treatment within the week before entering the trial.
- People who, in the judgment of the trial doctors, may not be able to follow the trial's requirements.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +12077706670
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence and severity of dose-limiting toxicities (DLTs) following chemotherapy preparative regimen and infusion of CD5/CD7 chimeric antigen receptor (CAR) T cells
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.